Interferon beta-1a for multiple sclerosis: Old drug, new clothes

The Lancet Neurology

Volumn 13, Issue 7, 2014, Pages 638-639

  Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; MACROGOL; PEGADEMASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON BETA1A; PEGVISOMANT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIGEN PRESENTING CELL; COVALENT BOND; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG UPTAKE; GLOMERULUS FILTRATION RATE; HUMAN; HYDRODYNAMICS; IMMUNOGENICITY; LIGAND BINDING; MACROPHAGE; MEDICATION COMPLIANCE; MOLECULAR SIZE; MULTIPLE SCLEROSIS; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; SYSTEMIC CIRCULATION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYETHYLENE GLYCOLS;

EID: 84902533614     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70100-0     Document Type: Note

References (14)

1. Wingerchuk DM, Carter JL Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014, 89:225-240.
2. Oh J, Calabresi PA Emerging injectable therapies for multiple sclerosis. Lancet Neurol 2013, 12:1115-1126.
3. Calabresi P, Kieseier BC, Douglas LA, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014, published online May 1. http://dx.doi.org/10.1016/S1474-4422(14)70068-7.
4. Nikfar S, Rahmini R, Abdollahi M A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type. Clin Ther 2010, 32:1871-1888.
5. Neuhaus O, Kieseier BC, Hartung HP Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 2007, 259:27-37.
6. Pasut G, Veronese FM State of the art in PEGylation: the great versatility after forty years of research. J Con Rel 2012, 161:461-472.
7. Kang JS, Deluca PD, Lee KC Emerging pegylated drugs. Expert Opin Emerging Drugs 2009, 14:363-370.
8. Hu X, Miller L, Richman S, et al. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology and biology. J Clin Pharmacol 2012, 52:789-808.
9. Hemmer B, Stüve O, Kieseier B, et al. Immune responses to immunotherapy: the role of neutralizing antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005, 4:403-412.
10. Solberg-Sorensen P New management algorithms in multiple sclerosis. Curr Opin Neurol 2014, 27:246-259.
11. Hartung HP, Kieseier BC The new therapeutic landscape in multiple sclerosis. Curr Opin Neurol 2014, 27:243-245.
12. Clanet M, Wolinsky JS, Ashton RJ, et al. Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult Scler 2013, published online Nov 30. 10.1177/1352458513513207.
13. Bevan CJ, Cree BA Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?. JAMA Neurol 2014, 71:269-270.
14. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012, 79:1130-1135.